SCHEMBL7216783

SCHEMBL7216783

CCCOCCOc1ccccc1COc1ccc2c(c1)C=C(C(=O)O)CCS2(=O)=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.35
KMT2A Q03164 4/20 0.34
ALDH1A1 P00352 3/20 0.34
PTK2B Q14289 1/20 0.34
LMNA P02545 3/20 0.34
MAPT P10636 1/20 0.34
PARP14 Q460N5 1/20 0.33
PARP10 Q53GL7 1/20 0.33
KDM4E B2RXH2 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 2/20 0.32
ALOX5 P09917 2/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
SLC10A2 Q12908 1/20 0.32
PTGES O14684 1/20 0.31
PPARG P37231 1/20 0.31
SLC26A4 O43511 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
FFAR1 O14842 1/20 0.31
TLR8 Q9NR97 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7215840 0.95 PPARD (0.37) PPARDKMT2APARP14PARP10KDM4E
SCHEMBL7218231 0.94 MAPT (0.34) PPARDKMT2AALDH1A1PTK2BLMNA
SCHEMBL7218151 0.91 PPARD (0.34) PPARDKMT2AALDH1A1LMNAMAPT
SCHEMBL7217018 0.89 PARP14 (0.36) ALDH1A1LMNAMAPTPARP14PARP10
SCHEMBL7216417 0.86 PPARD (0.42) PPARDKMT2AALOX5PTGESPPARG
SCHEMBL7222714 0.86 FFAR4 (0.32) PTGDR2FFAR1
SCHEMBL7216335 0.86 PARP10 (0.45) KMT2AALDH1A1MAPTPARP14PARP10
SCHEMBL7218190 0.86 PPARD (0.43) PPARDKMT2AMAPTALOX5PTGES
SCHEMBL7215961 0.85 HRH3 (0.39) KMT2ALMNAKDM4ESMN1; SMN2ALOX5
SCHEMBL7218226 0.85 PARP14 (0.34) PPARDKMT2ALMNAMAPTPARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed